Jun 10, 2025
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Jun 09, 2025
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
May 14, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Apr 01, 2025
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
Feb 14, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Feb 06, 2025
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Jan 08, 2025
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Jan 07, 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Dec 27, 2024
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Nov 22, 2024
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
Nov 18, 2024
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
Nov 15, 2024
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
Nov 11, 2024
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR(TM) in Cancer Patients with Recurrent Solid Tumors
Sep 05, 2024
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Sep 05, 2024
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR(TM) (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Aug 12, 2024
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
Aug 12, 2024
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Aug 12, 2024
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
Aug 05, 2024
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.